Phyto-oestrogens

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 17, Issue 2, 2003, Pages 253-271

  Duncan, Alison M ^a   Phipps, William R ^b   Kurzer, Mindy S ^c  

^a UNIVERSITY OF GUELPH   (Canada)

^b UNIVERSITY OF ROCHESTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cancer; Cardiovascular disease; Health effects; Isoflavone; Lignan; Menopausal symptoms; Osteoporosis; Phyto oestrogen; Review; Safety

Indexed keywords

ANTIESTROGEN; BIOCHANIN A; COUMESTAN DERIVATIVE; DAIDZEIN; DIETHYLSTILBESTROL; ENTERODIOL; ENTEROLACTONE; ESTRADIOL; ESTROGEN; FORMONONETIN; GENISTEIN; GLUCOSIDASE; GLYCITEIN; ISOFLAVONE DERIVATIVE; LIGNAN; O NORANGOLENSIN; PHYTOESTROGEN; PLACEBO; SECOISOLARICIRESINOL; STEROID; TAMOXIFEN; UNCLASSIFIED DRUG; LIGNAN DERIVATIVE;

BREAST CANCER; CANCER; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL TRIAL; DIET; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOXICITY; DRUG URINE LEVEL; ENDOCRINE DISEASE; EVIDENCE BASED MEDICINE; EXTRACTION; HEALTH STATUS; HORMONE ACTION; HORMONE DEPENDENCE; HORMONE SUBSTITUTION; HUMAN; HYPOTHESIS; INTESTINE FLORA; MENOPAUSAL SYNDROME; META ANALYSIS; NONHUMAN; OSTEOPOROSIS; PLANT; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SOYBEAN; SYMPTOMATOLOGY; CANCER RISK; NUTRITION; PLANT PRODUCT;

EID: 0038038038     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-690X(02)00103-3     Document Type: Review

References (148)

1. Adlercreutz H. Phyto-oestrogens and cancer. Lancet Oncology 2002; 3: 364-373.
2. Reinli K & Block G. Phytoestrogen content of foods - A compendium of literature values. Nutrition and Cancer 1996; 26: 123-148.
3. Wang HJ & Murphy PA. Isoflavone content in commercial soybean foods. Journal of Agricultural and Food Chemistry 1994; 42: 1666-1673.
4. Wang HJ & Murphy PA. Isoflavone composition of American and Japanese soybeans in Iowa: Effects of variety, crop year, and location. Journal of Agricultural and Food Chemistry 1994; 42: 1674-1677.
5. Wakai K, Egami I, Kato K et al. Dietary intake and sources of isoflavones among Japanese. Nutrition and Cancer 1999; 33: 139-145.
6. Chen Z, Zheng W, Custer LJ et al. Usual dietary consumption of soy foods and its correlation with the excretion rate of isoflavonoids in overnight urine samples among Chinese women in Shanghai. Nutrition and Cancer 1999; 33: 82-87.
7. De Kleijn MJ, Van Der Schouw YT, Wilson PW et al. Intake of dietary phytoestrogens is low in post-menopausal women in the United States: The Framingham study. Journal of Nutrition 2001; 131: 1826-1832.
8. Thompson LU, Robb P, Serraino M & Cheung F. Mammalian lignan production from various foods. Nutrition and Cancer 1991; 16: 43-52.
9. Thompson LU, Rickard SE, Cheung F et al. Variability in anticancer lignan levels in flaxseed. Nutrition and Cancer 1997; 27: 26-30.
10. Setchell KD. Phytoestrogens: The biochemistry, physiology, and implications for human health of soy isoflavones. American Journal of Clinical Nutrition 1998; 68: 1333S-1346S.
11. Setchell KD & Cassidy A. Dietary isoflavones: Biological effects and relevance to human health. Journal of Nutrition 1999; 129: 758S-767S.
12. Setchell KDR & Aldercreutz H. Mammalian lignans and phyto-estrogens. Recent studies on their formation, metabolism and biological role in health and disease. In Rowland IR (ed) Role of the Gut Flora in Toxicity and Cancer. London: Academic Press, 1988.
13. Adlercreutz H, Fotsis T, Lampe J et al. Quantitative determination of lignans and isoflavonoids in plasma of omnivorous and vegetarian women by isotope dilution gas chromatography-mass spectrometry. Scandinavian Journal of Clinical and Laboratory Investigation 1993; 215: 5-18.
14. Adlercreutz H, Van Der Wildt J, Kinzel J et al. Lignan and isoflavonoid conjugates in human urine. Journal of Steroid Biochemistry and Molecular Biology 1995; 52: 97-103.
15. Karr SC, Lampe JW, Hutchins AM & Slavil JL. Urinary isoflavonoid excretion in humans is dose dependent at low to moderate levels of soy-protein consumption. American Journal of Clinical Nutrition 1997; 66: 46-51.
16. Lampe JW, Martini MC, Kurzer MS et al. Urinary lignan and isoflavonoid excretion in premenopausal women consuming flaxseed powder. American Journal of Clinical Nutrition 1994; 60: 122-128.
17. Nesbitt PD, Lam Y & Thompson LU. Human metabolism of mammalian lignan precursors in raw and processed flaxseed. American Journal of Clinical Nutrition 1999; 69: 549-555.
18. Jacobs Jr. DR, Pereira MA, Stumpf K et al. Whole grain food intake elevates serum enterolactone. British Journal of Nutrition 2002; 88: 111-116.
19. Mazur WM, Uehara M, Wahala K & Adlercreutz H. Phyto-oestrogen content of berries, and plasma concentrations and urinary excretion of enterolactone after a single strawberry-meal in human subjects. British Journal of Nutrition 2000; 83: 381-387.
20. Horner NK, Kristal AR, Prunty J et al. Dietary determinants of plasma enterolactone. Cancer Epidemiology, Biomarkers and Prevention 2002; 11: 121-126.
21. Parkin DM. Cancers of the breast, endometrium and ovary: Geographic correlations. European Journal of Cancer and Clinical Oncology 1989; 25: 1917-1925.
22. Lee HP, Gourley L, Duffy SW et al. Dietary effects on breast-cancer risk in Singapore. Lancet 1991; 337: 1197-1200.
23. Hirose K, Tajima K, Hamajima N et al. A large-scale, hospital-based case-control study of risk factors of breast cancer according to menopausal status. Japanese Journal of Cancer Research 1995; 86: 146-154.
24. Dai Q, Shu XO, Jin F et al. Population-based case-control study of soyfood intake and breast cancer risk in Shanghai. British Journal of Cancer 2001; 85: 372-378.
25. Wu AH, Ziegler RG, Horn-Ross PL et al. Tofu and risk of breast cancer in Asian-Americans. Cancer Epidemiology, Biomarkers Prevention 1996; 5: 901-906.
26. Murkies A, Dalais FS, Briganti EM et al. Phytoestrogens and breast cancer in post-menopausal women: A case control study. Menopause 2000; 7: 289-296.
27. Zheng W, Dai Q, Custer LJ et al. Urinary excretion of isoflavonoids and the risk of breast cancer. Cancer Epidemiology, Biomarkers and Prevention 1999; 8: 35-40.
28. Dai Q, Franke AA, Jin F et al. Urinary excretion of phytoestrogens and risk of breast cancer among Chinese women in Shanghai. Cancer Epidemiology, Biomarkers and Prevention 2002; 11: 815-821.
29. Ziegler RG, Hoover RN, Pike MC et al. Migration patterns and breast cancer risk in Asian-American women. Journal of the National Cancer Institute 1993; 85: 1819-1827.
30. Adlercreutz H, Fotsis T, Bannwart C et al. Determination of urinary lignans and phytoestrogen metabolites, potential antioestrogens and anticarcinogens, in urine of women on various habitual diets. Journal of Steroid Biochemistry 1986; 25: 791-797.
31. Adlercreutz H, Fotsis T, Heikkinen R et al. Excretion of the lignans enterolactone and enterodiol and of equol in omnivorous and vegetarian post-menopausal women and in women with breast cancer. Lancet 1982; ii: 1295-1299.
32. Ingram D, Sanders K, Kolybaba M & Lopez D. Case-control study of phyto-oestrogens and breast cancer. Lancet 1997; 350: 990-994.
33. McCann SE, Moysich KB, Freudenheim JL et al. The risk of breast cancer associated with dietary lignans differs by CYP17 genotype in women. Journal of Nutrition 2002; 132: 3036-3041.
34. Pietinen P, Stumpf K, Mannisto S et al. Serum enterolactone and risk of breast cancer: A case-control study in eastern Finland. Cancer Epidemiology, Biomarkers and Prevention 2001; 10: 339-344.
35. Hulten K, Winkvist A, Lenner P et al. An incident case-referent study on plasma enterolactone and breast cancer risk. European Journal of Nutrition 2002; 41: 168-176.
36. Thompson LU. Experimental studies on lignans and cancer. Baillière's Clinical Endocrinology and Metabolism 1998; 12: 691-705.
37. Yuan JM, Wang QS, Ross RK et al. Diet and breast cancer in Shanghai and Tianjin, China. British Journal of Cancer 1995; 71: 1353-1358.
38. Key TJ, Sharp GB, Appleby PN et al. Soya foods and breast cancer risk: A prospective study in Hiroshima and Nagasaki, Japan. British Journal of Cancer 1999; 81: 1248-1256.
39. Horn-Ross PL, John EM, Lee M et al. Phytoestrogen consumption and breast cancer risk in a multiethnic population: The Bay Area Breast Cancer Study. American Journal of Epidemiology 2001; 154: 434-441.
40. Den Tonkelaar I, Keinan-Boker L, Veer PV et al. Urinary phytoestrogens and postmenopausal breast cancer risk. Cancer Epidemiology, Biomarkers and Prevention 2001; 10: 223-228.
41. Clemons M & Goss P. Oestrogen and the risk of breast cancer. New England Journal of Medicine 2001; 344: 276-285.
42. Shutt DA & Cox RI. Steroid and phyto-oestrogen binding to sheep uterine receptors in vitro. Journal of Endocrinology 1972; 52: 299-310.
43. Kurzer MS. Hormonal effects of soy isoflavones: Studies in premenopausal and post-menopausal women. Journal of Nutrition 2000; 130: 660S-661S.
44. Kurzer MS. Hormonal effects of soy in premenopausal women and men. Journal of Nutrition 2002; 132: 570S-573S.
45. Xu X, Duncan AM, Merz BE & Kurzer MS. Effects of soy isoflavones on oestrogen and phytoestrogen metabolism in premenopausal women. Cancer Epidemiology, Biomarkers and Prevention 1998; 7: 1101-1108.
46. Xu X, Duncan AM, Wangen KE & Kurzer MS. Soy consumption alters endogenous oestrogen metabolism in post-menopausal women. Cancer Epidemiology, Biomarkers and Prevention 2000; 9: 781-786.
47. Haggans CJ, Hutchins AM, Olson BA et al. Effect of flaxseed consumption on urinary oestrogen metabolites in post-menopausal women. Nutrition and Cancer 1999; 33: 188-195.
48. Haggans CJ, Travelli EJ, Thomas W et al. The effect of flaxseed and wheat bran consumption on urinary oestrogen metabolites in premenopausal women. Cancer Epidemiology, Biomarkers and Prevention 2000; 9: 719-725.
49. Adlercreutz H, Bannwart C, Wahala K et al. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. Journal of Steroid Biochemistry and Molecular Biology 1993; 44: 147-153.
50. Krazeisen A, Breitling R, Moller G & Adamski J. Phytoestrogens inhibit human 17beta-hydroxysteroid dehydrogenase type 5. Molecular and Cellular Endocrinology 2001; 171: 151-162.
51. Lamartiniere CA, Cotroneo MS & Fritz WA. Genistein chemoprevention: Timing and mechanisms of action in murine mammary and prostate. Journal of Nutrition 2002; 132: 552S-558S.
52. Shu XO, Jin F, Dai Q et al. Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women. Cancer Epidemiology, Biomarkers and Prevention 2001; 10: 483-488.
53. Wu AH, Wan P, Hankin J et al. Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis 2002; 23: 1491-1496.
54. Pienta KJ, Goodson JA & Esper PS. Epidemiology of prostate cancer: Molecular and environmental clues. Urology 1996; 48: 676-683.
55. Adlercreutz H. Phytoestrogens: Epidemiology and a possible role in cancer protection. Environmental Health Perspectives 1995; 103(supplement 7): 103-112.
56. Adlercreutz H, Markkanen H & Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 1993; 342: 1209-1210.
57. Morton MS, Chan PS, Cheng C et al. Lignans and isoflavonoids in plasma and prostatic fluid in men: Samples from Portugal, Hong Kong, and the United Kingdom. Prostate 1997; 32: 122-128.
58. Shimizu H, Ross RK, Bernstein L et al. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. British Journal of Cancer 1991; 63: 963-966.
59. Severson RK, Nomura AM, Grove JS & Stemmermann GN. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Research 1989; 49: 1857-1860.
60. Jacobsen BK, Knutsen SF & Fraser GE. Does high soy milk intake reduce prostate cancer incidence? The adventist health study (United States). Cancer Causes Control 1998; 9: 553-557.
61. Kolonel LN, Hankin JH, Whittemore AS et al. Vegetables, fruits, legumes and prostate cancer: A multiethnic case-control study. Cancer Epidemiology, Biomarkers and Prevention 2000; 9: 795-804.
62. Strom SS, Yamamura Y, Duphorne CM et al. Phytoestrogen intake and prostate cancer: A case-control study using a new database. Nutrition and Cancer 1999; 33: 20-25.
63. Hebert JR, Hurley TG, Olendzki BC et al. Nutritional and socioeconomic factors in relation to prostate cancer mortality: A cross-national study. Journal of the National Cancer Institute 1998; 90: 1637-1647.
64. Lee MM, Wang RT, Hsing AW et al. Case-control study of diet and prostate cancer in China. Cancer Causes Control 1998; 9: 545-552.
65. Oishi K, Okada K, Yoshida O et al. A case-control study of prostatic cancer with reference to dietary habits. Prostate 1988; 12: 179-190.
66. Hirayama T. Epidemiology of prostate cancer with special reference to the role of diet. National Cancer Institute Monograph 1979; 53: 149-155.
67. Stattin P, Adlercreutz H, Tenkanen L et al. Circulating enterolactone and prostate cancer risk: A Nordic nested case-control study. International Journal of Cancer 2002; 99: 124-129.
68. Stephens FO. Phytoestrogens and prostate cancer: Possible preventive role. Medical Journal of Australia 1997; 167: 138-140.
69. Urban D, Irwin W, Kirk M et al. The effect of isolated soy protein on plasma biomarkers in elderly men with elevated serum prostate specific antigen. Journal of Urology 2001; 165: 294-300.
70. Demark-Wahnefried W, Price DT, Polascik TJ et al. Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: Exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features. Urology 2001; 58: 47-52.
71. Lopez-Otin C & Diamandis EP. Breast and prostate cancer: An analysis of common epidemiological, genetic, and biochemical features. Endocrine Reviews 1998; 19: 365-396.
72. Fritz WA, Wang J, Eltoum IE & Lamartiniere CA. Dietary genistein down-regulates androgen and oestrogen receptor expression in the rat prostate. Molecular and Cellular Endocrinology 2002; 186: 89-99.
73. Nagata C, Inaba S, Kawakami N et al. Inverse association of soy product intake with serum androgen and oestrogen concentrations in Japanese men. Nutrition and Cancer 2000; 36: 14-18.
74. Evans BA, Griffiths K & Morton MS. Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. Journal of Endocrinology 1995; 147: 295-302.
75. Onozawa M, Fukuda K, Ohtani M et al. Effects of soybean isoflavones on cell growth and apoptosis of the human prostatic cancer cell line LNCaP. Japanese Journal of Clinical Oncology 1998; 28: 360-363.
76. Messina M & Bennink M. Soyfoods, isoflavones and risk of colonic cancer: A review of the in vitro and in vivo data. Bailliére's Clinical Endocrinology and Metabolism 1998; 12: 707-728.
77. Wu AH, Yang D & Pike MC. A meta-analysis of soyfoods and risk of stomach cancer: The problem of potential confounders. Cancer Epidemiology, Biomarkers and Prevention 2000; 9: 1051-1058.
78. McKeown-Eyssen GE & Bright-See E. Dietary factors in colon cancer: International relationships. Nutrition and Cancer 1984; 6: 160-170.
79. Tajima K & Tominaga S. Dietary habits and gastro-intestinal cancers: A comparative case-control study of stomach and large intestinal cancers in Nagoya, Japan. Japanese Journal of Cancer Research 1985; 76: 705-716.
80. Goodman MT, Wilkens LR, Hankin JH et al. Association of soy and fiber consumption with the risk of endometrial cancer. American Journal of Epidemiology 1997; 146: 294-306.
81. Lei B, Roncaglia V, Vigano R et al. Phytoestrogens and liver disease. Molecular and Cellular Endocrinology 2002; 193: 81-84.
82. Nagata C, Takatsuka N, Kurisu Y & Shimizu H. Decreased serum total cholesterol concentration is associated with high intake of soy products in Japanese men and women. Journal of Nutrition 1998; 128: 209-213.
83. De Kleijn MJ, Van Der Schouw YT, Wilson PW et al. Dietary intake of phytoestrogens is associated with a favorable metabolic cardiovascular risk profile in post-menopausal U.S. women: The Framingham study. Journal of Nutrition 2002; 132: 276-282.
84. Van Der Schouw YT, Pijpe A, Lebrun CE et al. Higher usual dietary intake of phytoestrogens is associated with lower aortic stiffness in post-menopausal women. Arteriosclerosis, Thrombosis, and Vascular Biology 2002; 22: 1316-1322.
85. Vanharanta M, Voutilainen S, Lakka TA et al. Risk of acute coronary events according to serum concentrations of enterolactone: A prospective population-based case-control study. Lancet 1999; 354: 2112-2115.
86. Anderson JW, Johnstone BM & Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. New England Journal of Medicine 1995; 333: 276-282.
87. Crouse JR, Morgan III T, Terry JG et al. A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Archives of Internal Medicine 1999; 159: 2070-2076.
88. Merz-Demlow BE, Duncan AM, Wangen KE et al. Soy isoflavones improve plasma lipids in normocholesterolemic, premenopausal women. American Journal of Clinical Nutrition 2000; 71: 1462-1469.
89. Wangen KE, Duncan AM, Xu X & Kurzer MS. Soy isoflavones improve plasma lipids in normocholesterolemic and mildly hypercholesterolemic post-menopausal women. American Journal of Clinical Nutrition 2001; 73: 225-231.
90. Gardner CD, Newell KA, Cherin R & Haskell WL. The effect of soy protein with or without isoflavones relative to milk protein on plasma lipids in hypercholesterolemic post-menopausal women. American Journal of Clinical Nutrition 2001; 73: 728-735.
91. Nestel PJ, Pomeroy S, Kay S et al. Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women. Journal of Clinical Endocrinology and Metabolism 1999; 84: 895-898.
92. Dewell A, Hollenbeck CB & Bruce B. The effects of soy-derived phytoestrogens on serum lipids and lipoproteins in moderately hypercholesterolemic post-menopausal women. Journal of Clinical Endocrinology and Metabolism 2002; 87: 118-121.
93. Clarkson TB. Soy, soy phytoestrogens and cardiovascular disease. Journal of Nutrition 2002; 132: 566S-569S.
94. Jenkins DJ, Kendall CW, Vidgen E et al. Health aspects of partially defatted flaxseed, including effects on serum lipids, oxidative measures, and ex vivo androgen and progestin activity: A controlled crossover trial. American Journal of Clinical Nutrition 1999; 69: 395-402.
95. Lucas EA, Wild RD, Hammond LJ et al. Flaxseed improves lipid profile without altering biomarkers of bone metabolism in post-menopausal women. Journal of Clinical Endocrinology and Metabolism 2002; 87: 1527-1532.
96. Anthony MS, Clarkson TB & Williams JK. Effects of soy isoflavones on atherosclerosis: Potential mechanisms. American Journal of Clinical Nutrition 1998; 68: 1390S-1393S.
97. Wiseman H, O'Reilly JD, Adlercreutz H et al. Isoflavone phytoestrogens consumed in soy decrease F(2)-isoprostane concentrations and increase resistance of low-density lipoprotein to oxidation in humans. American Journal of Clinical Nutrition 2000; 72: 395-400.
98. Vanharanta M, Voutilainen S, Nurmi T et al. Association between low serum enterolactone and increased plasma F2-isoprostanes, a measure of lipid peroxidation. Atherosclerosis 2002; 160: 465-469.
99. Nestel PJ, Yamashita T, Sasahara T et al. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arteriosclerosis, Thrombosis and Vascular Biology 1997; 17: 3392-3398.
100. Amonkar MM & Mody R. Developing profiles of post-menopausal women being prescribed oestrogen therapy to prevent osteoporosis. Journal of Community Health 2002; 27: 335-350.
101. Nelson HD, Humphrey LL, Nygren P et al. Postmenopausal hormone replacement therapy: Scientific review. Journal of the American Medical Association 2002; 288: 872-881.
102. Messina M & Messina V. Soyfoods, soybean isoflavones, and bone health: A brief overview. Journal of Renal Nutrition 2000; 10: 63-68.
103. Gennari C, Agnusdei D, Crepaldi G et al. Effect of ipriflavone - A synthetic derivative of natural isoflavones - On bone mass loss in the early years after menopause. Menopause 1998; 5: 9-15.
104. Lauderdale DS, Jacobsen SJ, Furner SE et al. Hip fracture incidence among elderly Asian-American populations. American Journal of Epidemiology 1997; 146: 502-509.
105. Tsuchida K, Mizushima S, Toba M & Soda K. Dietary soybeans intake and bone mineral density among 995 middle-aged women in Yokohama. Journal of Epidemiology 1999; 9: 14-19.
106. Horiuchi T, Onouchi T, Takahashi M et al. Effect of soy protein on bone metabolism in postmenopausal Japanese women. Osteoporosis International 2000; 11: 721-724.
107. Kritz-Silverstein D & Goodman-Gruen DL. Usual dietary isoflavone intake, bone mineral density, and bone metabolism in post-menopausal women. Journal of Women's Health and Gender-Based Medicine 2002; 11: 69-78.
108. Kardinaal AF, Morton MS, Bruggemann-Rotgans IE & Van Beresteijn EC. Phyto-oestrogen excretion and rate of bone loss in post-menopausal women. European Journal of Clinical Nutrition 1998; 52: 850-855.
109. Nagata C, Shimizu H, Takami R et al. Soy product intake and serum isoflavonoid and estradiol concentrations in relation to bone mineral density in post-menopausal Japanese women. Osteoporosis International 2002; 13: 200-204.
110. Potter SM, Baum JA & Teng H. Soy protein and isoflavones: Their effects on blood lipids and bone density in post-menopausal women. American Journal of Clinical Nutrition 1998; 68: 1375S-1379S.
111. Alekel DL, Germain AS, Peterson CT et al. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. American Journal of Clinical Nutrition 2000; 72: 844-852.
112. Scambia G, Mango D, Signorile PG et al. Clinical effects of a standardized soy extract in post-menopausal women: A pilot study. Menopause 2000; 7: 105-111.
113. Scheiber MD, Liu JH, Subbiah MT et al. Dietary inclusion of whole soy foods results in significant reductions in clinical risk factors for osteoporosis and cardiovascular disease in normal postmenopausal women. Menopause 2001; 8: 384-392.
114. Murkies AL, Lombard C, Strauss BJ et al. Dietary flour supplementation decreases post-menopausal hot flushes: Effect of soy and wheat. Maturitas 1995; 21: 189-195.
115. Hsu CS, Shen WW, Hsueh YM & Yeh SL. Soy isoflavone supplementation in post-menopausal women. Effects on plasma lipids, antioxidant enzyme activities and bone density. Journal of Reproductive Medicine 2001; 46: 221-226.
116. Wangen KE, Duncan AM, Merz-Demlow BE et al. Effects of soy isoflavones on markers of bone turnover in premenopausal and post-menopausal women. Journal of Clinical Endocrinology and Metabolism 2000; 85: 3043-3048.
117. Chiechi L, Secreto G, D'Amore M et al. Efficacy of a soy rich diet in preventing post-menopausal osteoporosis: The Menfis randomized trial. Maturitas 2002; 42: 295-300.
118. Kim MK, Chung BC, Yu VY et al. Relationships of urinary phyto-oestrogen excretion to BMD in postmenopausal women. Clinical Endocrinology (Oxford) 2002; 56: 321-328.
119. Dalais FS, Rice GE, Wahlqvist ML et al. Effects of dietary phytoestrogens in post-menopausal women. Climacteric 1998; 1: 124-129.
120. Adlercreutz H, Hamalainen E, Gorbach S & Goldin B. Dietary phyto-oestrogens and the menopause in Japan. Lancet 1992; 339: 1233.
121. Nagata C, Shimizu H, Takami R et al. Hot flushes and other menopausal symptoms in relation to soy product intake in Japanese women. Climacteric 1999; 2: 6-12.
122. Nagata C, Takatsuka N, Kawakami N & Shimizu H. Soy product intake and hot flushes in Japanese women: Results from a community-based prospective study. American Journal of Epidemiology 2001; 153: 790-793.
123. Murkies AL, Wilcox G & Davis SR. Clinical review 92: Phytoestrogens. Journal of Clinical Endocrinology and Metabolism 1998; 83: 297-303.
124. Knight DC, Howes JB, Eden JA & Howes LG. Effects on menopausal symptoms and acceptability of isoflavone-containing soy powder dietary supplementation. Climacteric 2001; 4: 13-18.
125. Van Patten CL, Olivotto IA, Chambers GK et al. Effect of soy phytoestrogens on hot flushes in post-menopausal women with breast cancer: A randomized, controlled clinical trial. Journal of Clinical Oncology 2002; 20: 1449-1455.
126. Davis SR. Phytoestrogen therapy for menopausal symptoms? British Medical Journal 2001; 323: 354-355.
127. Albertazzi P, Pansini F, Bonaccorsi G et al. The effect of dietary soy supplementation on hot flushes. Obstetrics and Gynecology 1998; 91: 6-11.
128. Washburn S, Burke GL, Morgan T & Anthony M. Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. Menopause 1999; 6: 7-13.
129. Brzezinski A, Adlercreutz H, Shaoul R et al. Short-term effects of phytoestrogen-rich diet on post-menopausal women. Journal of the North American Menopause Society 1997; 4: 89-94.
130. Faure ED, Chantre P & Mares P. Effects of a standardized soy extract on hot flushes: A multicenter, double-blind, randomized, placebo-controlled study. Menopause 2002; 9: 329-334.
131. Han KK, Soares Jr. JM, Haidar MA et al. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. Obstetrics and Gynecology 2002; 99: 389-394.
132. Baber RJ, Templeman C, Morton T et al. Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women. Climacteric 1999; 2: 85-92.
133. Knight DC, Howes JB & Eden JA. The effect of Promensil, an isoflavone extract, on menopausal symptoms. Climacteric 1999; 2: 79-84.
134. Quella SK, Loprinzi CL, Barton DL et al. Evaluation of soy phytoestrogens for the treatment of hot flushes in breast cancer survivors: A North Central Cancer Treatment Group Trial. Journal of Clinical Oncology 2000; 18: 1068-1074.
135. Mendez MA, Anthony MS & Arab L. Soy-based formulae and infant growth and development: A review. Journal of Nutrition 2002; 132: 2127-2130.
136. Setchell KD, Zimmer-Nechemias L, Cai J & Heubi JE. Isoflavone content of infant formulas and the metabolic fate of these phytoestrogens in early life. American Journal of Clinical Nutrition 1998; 68: 1453S-1461S.
137. Strom BL, Schinnar R, Ziegler EE et al. Exposure to soy-based formula in infancy and endocrinological and reproductive outcomes in young adulthood. Journal of the American Medical Association 2001; 286: 807-814.
138. Badger TM, Ronis MJ, Hakkak R et al. The health consequences of early soy consumption. Journal of Nutrition 2002; 132: 559S-565S.
139. Messina MJ & Loprinzi CL. Soy for breast cancer survivors: A critical review of the literature. Journal of Nutrition 2001; 131: 3095S-3108S.
140. Allred CD, Allred KF, Ju YH et al. Soy diets containing varying amounts of genistein stimulate growth of oestrogen-dependent (MCF-7) tumours in a dose-dependent manner. Cancer Research 2001; 61: 5045-5050.
141. Ju YH, Allred CD, Allred KF et al. Physiological concentrations of dietary genistein dose-dependently stimulate growth of oestrogen-dependent human breast cancer (MCF-7) tumours implanted in athymic nude mice. Journal of Nutrition 2001; 131: 2957-2962.
142. Ju YH, Doerge DR, Allred KF et al. Dietary genistein negates the inhibitory effect of tamoxifen on growth of oestrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Research 2002; 62: 2474-2477.
143. Petrakis NL, Barnes S, King EB et al. Stimulatory influence of soy protein isolate on breast secretion in pre- and post-menopausal women. Cancer Epidemiology, Biomarkers and Prevention 1996; 5: 785-794.
144. Hargreaves DF, Potten CS, Harding C et al. Two-week dietary soy supplementation has an oestrogenic effect on normal premenopausal breast. Journal of Clinical Endocrinology and Metabolism 1999; 84: 4017-4024.
145. Setchell KD, Brown NM, Desai P et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. Journal of Nutrition 2001; 131: 1362S-1375S.
146. Setchell KD. Absorption and metabolism of soy isoflavones - From food to dietary supplements and adults to infants. Journal of Nutrition 2000; 130: 654S-655S.
147. Setchell KD, Brown NM, Zimmer-Nechemias L et al. Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability. American Journal of Clinical Nutrition 2002; 76: 447-453.
148. Busby MG, Jeffcoat AR, Bloedon LT et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones: Single-dose administration to healthy men. American Journal of Clinical Nutrition 2002; 75: 126-136.